Beximco Pharmaceuticals Past Earnings Performance
Past criteria checks 4/6
Beximco Pharmaceuticals has been growing earnings at an average annual rate of 9%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 13.4% per year. Beximco Pharmaceuticals's return on equity is 11.2%, and it has net margins of 13.3%.
Key information
9.0%
Earnings growth rate
9.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 13.4% |
| Return on equity | 11.2% |
| Net Margin | 13.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Beximco Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 44,946 | 5,957 | 11,368 | 0 |
| 30 Jun 24 | 44,392 | 5,830 | 11,112 | 0 |
| 31 Mar 24 | 43,085 | 5,330 | 10,873 | 0 |
| 31 Dec 23 | 41,652 | 4,916 | 10,706 | 0 |
| 30 Sep 23 | 40,639 | 4,720 | 10,480 | 0 |
| 30 Jun 23 | 39,267 | 4,614 | 10,200 | 0 |
| 31 Mar 23 | 37,974 | 4,477 | 10,033 | 0 |
| 31 Dec 22 | 37,379 | 4,629 | 9,592 | 0 |
| 30 Sep 22 | 35,987 | 5,105 | 9,463 | 0 |
| 30 Jun 22 | 34,669 | 5,123 | 9,101 | 0 |
| 31 Mar 22 | 33,660 | 5,738 | 8,887 | 0 |
| 31 Dec 21 | 32,062 | 6,097 | 8,393 | 0 |
| 30 Sep 21 | 31,037 | 5,519 | 7,837 | 0 |
| 30 Jun 21 | 29,494 | 5,128 | 7,470 | 0 |
| 31 Mar 21 | 28,269 | 4,578 | 6,918 | 0 |
| 31 Dec 20 | 27,517 | 4,017 | 6,802 | 0 |
| 30 Sep 20 | 26,235 | 3,724 | 6,581 | 0 |
| 30 Jun 20 | 25,612 | 3,515 | 6,451 | 0 |
| 31 Mar 20 | 25,056 | 3,405 | 6,221 | 0 |
| 31 Dec 19 | 24,202 | 3,251 | 6,068 | 0 |
| 30 Sep 19 | 23,735 | 3,143 | 5,900 | 0 |
| 30 Jun 19 | 22,817 | 3,033 | 5,689 | 0 |
| 31 Mar 19 | 21,724 | 2,852 | 5,470 | 0 |
| 31 Dec 18 | 20,188 | 2,708 | 5,053 | 0 |
| 30 Sep 18 | 18,823 | 2,647 | 4,661 | 0 |
| 30 Jun 18 | 17,717 | 2,537 | 4,356 | 0 |
| 31 Mar 18 | 16,924 | 2,513 | 4,159 | 0 |
| 31 Dec 17 | 16,517 | 2,431 | 4,054 | 0 |
| 30 Sep 17 | 16,022 | 2,356 | 3,983 | 0 |
| 30 Jun 17 | 15,509 | 2,227 | 3,829 | 0 |
| 31 Mar 17 | 14,687 | 2,224 | 3,480 | 0 |
| 31 Dec 16 | 14,271 | 2,133 | 3,390 | 0 |
| 30 Sep 16 | 13,736 | 2,060 | 3,342 | 0 |
| 30 Jun 16 | 13,356 | 1,965 | 3,263 | 0 |
| 31 Dec 15 | 12,966 | 1,954 | 3,266 | 0 |
| 30 Sep 15 | 12,573 | 1,804 | 3,082 | 0 |
| 30 Jun 15 | 12,134 | 1,813 | 2,992 | 0 |
| 31 Mar 15 | 11,628 | 1,605 | 2,867 | 0 |
| 31 Dec 14 | 11,207 | 1,528 | 2,755 | 0 |
| 30 Sep 14 | 11,139 | 1,476 | 2,806 | 0 |
| 30 Jun 14 | 10,847 | 1,471 | 2,732 | 0 |
| 31 Mar 14 | 10,804 | 1,452 | 2,686 | 0 |
| 31 Dec 13 | 10,491 | 1,405 | 2,619 | 0 |
Quality Earnings: R2WA has high quality earnings.
Growing Profit Margin: R2WA's current net profit margins (13.3%) are higher than last year (11.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: R2WA's earnings have grown by 9% per year over the past 5 years.
Accelerating Growth: R2WA's earnings growth over the past year (26.2%) exceeds its 5-year average (9% per year).
Earnings vs Industry: R2WA earnings growth over the past year (26.2%) did not outperform the Pharmaceuticals industry 28.7%.
Return on Equity
High ROE: R2WA's Return on Equity (11.2%) is considered low.